Updated March 24, 2020
The ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) and National Cancer Institute (NCI) are developing NCI-ComboMATCH, a successor to the NCI-MATCH / EAY131 precision medicine trial. Like the original trial, NCI-ComboMATCH will be a signal-seeking study. While NCI-MATCH treatments mostly consist of single drugs, NCI-ComboMATCH will test combinations of targeted drugs supported by preclinical in vivo evidence. The principal is to overcome drug resistance to single-agent therapy by developing genomically-directed targeted agent combinations.
All combinations in the new trial will be supported by robust, preclinical in vivo evidence. The hypothesis behind this trial is that in vivo evidence, in particular, patient-derived xenograft (PDX) and cell-line-derived xenograft (CDX) data, can be used to predict the benefit of drug combination therapy in multiple specified patient subgroups.
NCI-ComboMATCH will have an overall Master Control Document, managed by ECOG-ACRIN, and several treatment arms (subprotocols) that will be organized into small groups, or ‘cassettes’ for administrative reasons. Each cassette will have four to six treatment arms. The master protocol will contain rules for assigning patients to treatments and other guidelines.
Each of the five cooperative research groups in the NCI Clinical Trials Network (NCTN) will manage a cassette of subprotocols. ECOG-ACRIN will handle one along with managing the overall trial. The other network groups administering cassettes are the Alliance for Clinical Trials in Oncology, Children’s’ Oncology Group, NRG Oncology, and SWOG.
Like NCI-MATCH, the new trial will have multiple investigators leading each treatment arm. There will be opportunities for both junior and senior investigators to work alongside translational researchers.
NCI-ComboMATCH (EAY191) is funded by the National Cancer Institute (NCI) through its National Clinical Trials Network. NCI is part of the National Institutes of Health.